DOCSLIB.ORG

2020 Prescription Drug Formulary Basic/Basic Plus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Prescription Drug Formulary Basic/Basic Plus 2020 Prescription Drug Formulary Basic/Basic Plus PLEASE READ: This document contains information about the drugs we cover in your plan. This formulary was updated December 1, 2020 and is subject to change. Coverage is subject to the definitions, limitations, exclusions and parameters set forth in your official plan benefit documents. Please refer to your Certificate or Benefit Book for more information. C2382-RXX R12/20 Multi-Language Interpreter Services & Nondiscrimination Notice This document notifies individuals of how to seek assistance if they speak a language other than English. Spanish Oromo ATENCIÓN: Si habla español, tiene a su disposición XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, servicios gratuitos de asistencia lingüística. Llame al tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni 1-800-382-5729 (TTY: 711). argama. Bilbilaa 1-800-382-5729 (TTY: 711). Chinese Korean 注意:如果您使用繁體中文,您可以免費獲得語言援助服 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 務。請致電 1-800-382-5729 (TTY: 711)。 무료로 이용하실 수 있습니다. 1-800-382-5729 (TTY: 711)번으로 전화해 주십시오. German ACHTUNG: Wenn Sie Deutsch sprechen, stehen Italian Ihnen kostenlos sprachliche Hilfsdienstleistungen zur ATTENZIONE: In caso la lingua parlata sia l’italiano, Verfügung. Rufnummer: 1-800-382-5729 (TTY: 711). sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 1-800-382-5729 (TTY: 711). Arabic Japanese ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغویة تتوافر لك 注意事項:日本語を話される場合、無料の言語支援を ( بالمجان. اتصل برقم 5729-382-800-1 رقم ھاتف الصم والبكم 711). ご利用いただけます。1-800-382-5729 (TTY: 711) ま Pennsylvania Dutch で、お電話にてご連絡ください。 Wann du Deitsch schwetzscht, kannscht du mitaus Koschte ebber gricke, ass dihr helft mit die englisch Schprooch. Ruf Dutch selli Nummer uff: Call 1-800-382-5729 (TTY: 711). AANDACHT: Als u nederlands spreekt, kunt u gratis gebruikmaken van de taalkundige diensten. Bel Russian 1-800-382-5729 (TTY: 711). ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Ukrainian Звоните 1-800-382-5729 (телетайп: 711). УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної French підтримки. Телефонуйте за номером 1-800-382-5729 ATTENTION: Si vous parlez français, des services (телетайп: 711). d’aide linguistique vous sont proposés gratuitement. Appelez le 1-800-382-5729 (ATS: 711). Romanian ATENT, IE: Dacă vorbit,i limba română, vă stau la Vietnamese dispozit,ie servicii de asistent,ă lingvistică, gratuit. CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ Sunat,i la 1-800-382-5729 (TTY: 711). miễn phí dành cho bạn. Gọi số 1-800-382-5729 (TTY: 711). Tagalog Navajo PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari Díí baa akó nínízin: Díí saad bee yáníłti’ go Diné kang gumamit ng mga serbisyo ng tulong sa wika nang Bizaad, saad bee áká’ánída’áwo’dę΄ę΄’, t’áá jiik’eh, éí walang bayad. Tumawag sa 1-800-382-5729 (TTY: 711). ná hólǫ´, kojį’ hódíílnih 1-800-382-5729 (TTY: 711). Please Note: Products marketed by Medical Mutual may be underwritten by one of its subsidiaries, such Order Number: Z8188-MCA R4/19 as Medical Health Insuring Corporation of Ohio or Dept of Ins. Filing Number: Z8188-MCA R9/16 MedMutual Life Insurance Company. QUESTIONS ABOUT YOUR BENEFITS OR OTHER INQUIRIES ABOUT YOUR HEALTH INSURANCE SHOULD BE DIRECTED TO MEDICAL MUTUAL’S CUSTOMER CARE DEPARTMENT AT 1-800-382-5729. Nondiscrimination Notice Medical Mutual of Ohio complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex in its operation of health programs and activities. Medical Mutual does not exclude people or treat them differently because of race, color, national origin, age, disability or sex in its operation of health programs and activities. n Medical Mutual provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters, and written information in other formats (large print, audio, accessible electronic formats, etc.). n Medical Mutual provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services or if you believe Medical Mutual failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, with respect to your health care benefits or services, you can submit a written complaint to the person listed below. Please include as much detail as possible in your written complaint to allow us to effectively research and respond. Civil Rights Coordinator Medical Mutual of Ohio 2060 East Ninth Street Cleveland, OH 44115-1355 MZ: 01-10-1900 Email: [email protected] You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights. n Electronically through the Office for Civil Rights Complaint Portal available at: ocrportal.hhs.gov/ocr/portal/lobby.jsf n By mail at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F HHH Building Washington, DC 20201-0004 n By phone at: 1-800-368-1019 (TDD: 1-800-537-7697) n Complaint forms are available at: hhs.gov/ocr/office/file/index.html Products marketed by Medical Mutual may be underwritten by one of its subsidiaries, such as Medical Health Insuring Corporation of Ohio or MedMutual Life Insurance Company. Basic/Basic Plus Formulary What is the Basic/Basic Plus formulary? What do I do if my medication requires prior The Basic/Basic Plus formulary is a list of authorization or step therapy, or has a medications covered by your plan. The quantity limit? formulary includes five tiers: You, your doctor or your pharmacist can call 1. Generic (lowest out-of-pocket cost) Express Scripts at 1-800-753-2851 to begin the 2. Preferred brand review process for medications that require 3. Non-preferred brand prior authorization or step therapy, or that have 4. Specialty (highest out-of-pocket cost) a quantity limit. After contacting Express 5. Preventive ($0 out-of-pocket cost) Scripts, your doctor will receive a form to fill out and fax back to Express Scripts. Express Refer to your Certificate or Benefit Book for Scripts will send you and your doctor a letter information about your cost share, including confirming if coverage has been approved copays, coinsurance and/or deductibles. Not all (usually within three business days of receiving tiers apply to all plans. the necessary information). • If you ordered your prescription through mail If you are a member of a plan that includes a order, Express Scripts will automatically preferred pharmacy network (e.g., CLE-Care), send it to you once coverage is approved. those preferred pharmacies may offer lower • If you tried to fill your prescription at a retail cost sharing to help you save money. Check pharmacy, you will need to return to the your benefit materials for more details. pharmacy to pick up your medication. Your plan may exclude certain medications. Does the Basic/Basic Plus formulary include Please refer to your Certificate or Benefit Book generic and brand medications? for more information. Yes. The Basic/Basic Plus formulary includes a variety of generic and brand medications to How do I use the Basic/Basic Plus help you pay less out of pocket. formulary? Covered medications are organized two ways in Generic medications are shown in this the Basic/Basic Plus formulary: document in lower-case italic letters. Generics 1. By condition are approved by the U.S. Food and Drug 2. By name Administration (FDA) as having the same active ingredient as their brand-name counterparts. In If you know what your medication is used to addition, the FDA requires generics to be just treat, you can look it up by condition in the front as safe and strong as their brand-name of the document. If you don’t know what counterparts so you get the same medical condition it is used to treat, you can look for it in benefit. the alphabetical Index at the back of the document. Brand medications are shown in this document in ALL CAPITAL LETTERS. Does the Basic/Basic Plus formulary include brand medications are covered by your plan, specialty medications? and which may help you save money. Yes. Specialty medications are used to treat certain complex medical conditions and may If you are a member of a plan that includes a require special handling, instruction, or preferred pharmacy network (e.g., CLE-Care), monitoring. Many plans limit you to a 30-day those preferred pharmacies may offer lower supply for most specialty medications and/or cost sharing to help you save money. Check require you to fill prescriptions for these your benefit materials for more details. medications through one of Medical Mutual’s contracted specialty pharmacies, Accredo or Do I have to use mail order for my Gentry. maintenance medications? Depending on your plan, you may be required If you are a member of a plan that includes a to use mail order for your maintenance preferred pharmacy network (e.g., CLE-Care), medications (those you take for three months or you may be required to use specific preferred more). Check your Certificate or Benefit Book pharmacies for specialty drugs. for details. (Note: If you are a member of a CLE-Care plan, you must fill mail-order Please check your Certificate or Benefit Book medications through the MetroHealth Central for more details about ordering specialty drugs. Fill Pharmacy. Visit metrohealth.org/pharmacy for more information and to download a form.) Are there other limitations or coverage rules in addition to what are listed in this guide? Even if you are not required to do so, you may Yes.
Load more

Recommended publications
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • The Metabolism of Anabolic Agents in the Racing Greyhound
    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Sports Drug Testing and Toxicology TOP ARTICLES SUPPLEMENT
    Powered by Sports drug testing and toxicology TOP ARTICLES SUPPLEMENT CONTENTS REVIEW: Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis Vol. 8 Issue 12 REVIEW: Current status and recent advantages in derivatization procedures in human doping control Bioanalysis Vol. 7 Issue 19 REVIEW: Advances in the detection of designer steroids in anti-doping Bioanalysis Vol. 6 Issue 6 Review For reprint orders, please contact [email protected] 8 Review 2016/05/28 Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis LC–MS/MS is useful for qualitative and quantitative analysis of ‘doped’ biological Zhanliang Wang‡,1, samples from athletes. LC–MS/MS-based assays at low-mass resolution allow fast Jianghai Lu*,‡,2, and sensitive screening and quantification of targeted analytes that are based on Yinong Zhang1, Ye Tian2, 2 ,2 preselected diagnostic precursor–product ion pairs. Whereas LC coupled with high- Hong Yuan & Youxuan Xu** 1Food & Drug Anti-doping Laboratory, resolution/high-accuracy MS can be used for identification and quantification, both China Anti-Doping Agency, 1st Anding have advantages and challenges for routine analysis. Here, we review the literature Road, ChaoYang District, Beijing 100029, regarding various quantification methods for measuring prohibited substances in PR China athletes as they pertain to World Anti-Doping Agency regulations. 2National Anti-doping Laboratory, China Anti-Doping Agency, 1st Anding Road, First draft submitted:
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41
    Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10065-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, Tennessee Investigators: Jeff Andrews, M.D. Amanda Yunker, D.O., M.S.C.R. W. Stuart Reynolds, M.D. Frances E. Likis, Dr.P.H., N.P., C.N.M. Nila A. Sathe, M.A., M.L.I.S. Rebecca N. Jerome, M.L.I.S., M.P.H. AHRQ Publication No. 11(12)-EHC088-EF January 2012 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10065-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Effects of Administering Testosterone Undecanoate in Rats
    Brazilian Journal of Pharmaceutical Sciences vol. 46, n. 1, jan./mar., 2010 Article Effects of administering testosterone undecanoate in rats subjected to physical exercise: effects on the estrous cycle, motor behavior and morphology of the liver and kidney Moisés Tolentino Bento-Silva1,3,*, Maria do Carmo de Carvalho e Martins2, Francisco Leonardo Torres-Leal1,3, Talvany Luiz Barros3, Ingrid Lara do Nascimento Ferreira de Carvalho2, Hugo Aparecido Carvalho Filho2, Fernanda Regina de Castro Almeida3 1Department of Physical Education, Federal University of Piauí, 2Department of Physiology and Biophysics, Federal University of Piauí, 3Medicinal Plants Research Center, Federal University of Piauí The aim of the work was evaluate the effects of testosterone undecanoate (TU) treatment combined with moderate physical training on: the estrous cycle, body weight (BW), motor behavior (MB), and the morphohistology of the reproductive system, the liver and kidney in rats. Female Wistar rats (180 g - 250 g) were divided as follows: sedentary + TU (S + TU), trained + TU (T + TU), sedentary + vehicle (S + V), trained + vehicle (T + V). The rats swam 50 min/Day, strapped with a 5% BW load, for 4 weeks. During this training, (BW) was monitored daily as well as the estrous cycle (EC) by vaginal smear. The TU (15 mg/kg s.c) was administered 3 times/week for 4 weeks. At the end of the study, data on MB, BW and morphohistopathological changes in viscera were compiled. The (T + TU) group had on average, a higher (BW) in the fourth week compared to the first week, and (BW) higher than (S + V) and (S + TU) groups.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • The Misuse of Drugs Regulations (Northern Ireland) 2002
    Document Generated: 2020-07-28 Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format. SCHEDULE 4 Part II Controlled Drugs excepted from the Prohibition on possession when in the form a Medicinal product;excluded from application of offences arising from the probition on importation and exportation when imported or exported in the form of a medicinal product by any person for administration to himself; and subject to the requirements of regulations 22, 23, 26 and 27 1. The following substances, namely— Atamestane Bolandiol Bolasterone Bolazine Boldenone Bolenol Bolmantalate Calusterone 4-Chloromethandienone Clostebol Drostanolone Enestobol Epitiostanol Ethyloestrenol Fluoxymesterone Formebolone Furazabol Mebolazine Mepitiostane Mesabolone Mestanolone Mesterolone Methandienone Methandriol Methenolone Methyltestosterone Metribolone Mibolerone Nandrolone Norboletone 1 Document Generated: 2020-07-28 Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format. Norclostebol Norethandrolone Ovandrotone Oxabolone Oxandrolone Oxymesterone Oxymetholone Prasterone Propetandrol Quinbolone Roxibolone Silandrone Stanolone Stanozolol Stenbolone Testosterone Thiomesterone Trenbolone 2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17- hydroxyestran-3-one by modification in any of the following ways, that is to say— (a) by further substitution at position 17 by a methyl or ethyl group; (b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position; (c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring; (d) by fusion of ring A with a heterocyclic system.
    [Show full text]